Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zdeněk Kejík, Robert Kaplánek, Petr Dytrych, Michal Masařík, Kateřina Veselá, Nikita Abramenko, David Hoskovec, Martina Vašáková, Jarmila Králová, Pavel Martásek, Milan Jakubek
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	CTCs NSCLCs metastasis suppression curcumin flavonoids Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/a9212fe2fd9443cd854b6088bd96b44c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a9212fe2fd9443cd854b6088bd96b44c
record_format	dspace
spelling	oai:doaj.org-article:a9212fe2fd9443cd854b6088bd96b44c2021-11-25T18:41:24ZCirculating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design10.3390/pharmaceutics131118791999-4923https://doaj.org/article/a9212fe2fd9443cd854b6088bd96b44c2021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1879https://doaj.org/toc/1999-4923Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial–mesenchymal transition, and migration of cancer cells).Zdeněk KejíkRobert KaplánekPetr DytrychMichal MasaříkKateřina VeseláNikita AbramenkoDavid HoskovecMartina VašákováJarmila KrálováPavel MartásekMilan JakubekMDPI AGarticleCTCsNSCLCsmetastasis suppressioncurcuminflavonoidsPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1879, p 1879 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CTCs NSCLCs metastasis suppression curcumin flavonoids Pharmacy and materia medica RS1-441
spellingShingle	CTCs NSCLCs metastasis suppression curcumin flavonoids Pharmacy and materia medica RS1-441 Zdeněk Kejík Robert Kaplánek Petr Dytrych Michal Masařík Kateřina Veselá Nikita Abramenko David Hoskovec Martina Vašáková Jarmila Králová Pavel Martásek Milan Jakubek Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
description	Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial–mesenchymal transition, and migration of cancer cells).
format	article
author	Zdeněk Kejík Robert Kaplánek Petr Dytrych Michal Masařík Kateřina Veselá Nikita Abramenko David Hoskovec Martina Vašáková Jarmila Králová Pavel Martásek Milan Jakubek
author_facet	Zdeněk Kejík Robert Kaplánek Petr Dytrych Michal Masařík Kateřina Veselá Nikita Abramenko David Hoskovec Martina Vašáková Jarmila Králová Pavel Martásek Milan Jakubek
author_sort	Zdeněk Kejík
title	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
title_short	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
title_full	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
title_fullStr	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
title_full_unstemmed	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
title_sort	circulating tumour cells (ctcs) in nsclc: from prognosis to therapy design
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a9212fe2fd9443cd854b6088bd96b44c
work_keys_str_mv	AT zdenekkejik circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT robertkaplanek circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT petrdytrych circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT michalmasarik circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT katerinavesela circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT nikitaabramenko circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT davidhoskovec circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT martinavasakova circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT jarmilakralova circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT pavelmartasek circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign AT milanjakubek circulatingtumourcellsctcsinnsclcfromprognosistotherapydesign
_version_	1718410793544843264

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

Ejemplares similares